CARMIEL, Israel, Dec. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein...
Read More Details
Finally We wish PressBee provided you with enough information of ( Protalix BioTherapeutics Issues 2025 Letter to Stockholders )
Also on site :
- Fresh sirens in north Israel warning of Iran missiles: army
- Target's 'Top-Selling' $5 Backpack Is Heading Back to Stores This Year
- SMB-focused Finom closes €115M as European fintech heats up